Las Vegas, NV -- (SBWIRE) -- 12/13/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Goodrich Petroleum Corporation (NYSE:GDP), Idera Pharmaceuticals Inc(NASDAQ:IDRA), ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC), Elephant Talk Communications Corp(NYSEMKT:ETAK)
Goodrich Petroleum Corporation (NYSE:GDP) decreased -3.32% at the price of $16.33 recently on a traded volume of 1.62 million shares, in comparison to 1.97 million shares of average trading volume. So far this year, the stock is down over -75.32%.
The company has a total market capitalization of $713.61 million and its total outstanding shares are 43.67 million. Goodrich Petroleum Corporation is an independent oil and natural gas company engaged in exploration, development and production of oil and natural gas on properties primarily in Northwest Louisiana, East Texas and South Texas.
Has GDP Found The Bottom and Ready To Move Up? Find Out Here
Idera Pharmaceuticals Inc(NASDAQ:IDRA) plunged -4.28% at the trading price of $3.13 on a traded volume of 1.86 million shares till now, whereas its average trading volume is 1.18 million shares. In the last three months, the stock is up 80.35%. The Intra-day range for the stock is $2.94 and $3.37. Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs).
Has IDRA Found The Bottom And Ready To Gain Momentum? Find Out Here
ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC) dropped down -5.45% at the $1.04 recently. So far in three months, the stock is down -62.23%. The 52-week range for the stock is $0.99 and $1.10. Its introductory price for the day was $1.04, with the overall traded volume of 4.94 million shares. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Why Should Investors Buy IMUC After the Recent Fall? Just Go Here and Find Out
Elephant Talk Communications Corp(NYSEMKT:ETAK), after opening its shares at the price of $1.40, jumped up 5.79% , its recent trading price was $1.28 for the day. The stock moved on a traded volume of 677,425.00 shares, in comparison to 841,785.00 shares of average trading volume. Elephant Talk Communications Corp. is a provider of mobile networking software and services. The Company provides operating software, managed services, cloud and Software as a Service (SaaS) solutions, an integrated transaction and delivery platform to the mobile telecommunications industry globally.
Why Should Investors Buy ETAK After The Recent Gain? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)